Initial Management of Heart Failure with Preserved Ejection Fraction (HFpEF)
Diagnostic Confirmation
- The American College of Cardiology and European Heart Journal recommend confirming HFpEF diagnosis using a two-step approach, first establishing heart failure symptoms with LVEF ≥50%, elevated natriuretic peptides, and evidence of structural heart disease or elevated filling pressures; if uncertain, proceed to stress testing 1
- The American College of Cardiology suggests ruling out HFpEF mimics such as cardiac amyloidosis, hypertrophic cardiomyopathy, or pericardial disease which may require specific treatments 2, 3
First-Line Pharmacological Management
Symptom Management
- The American College of Cardiology recommends loop diuretics as the cornerstone for symptom relief in congested patients, using the lowest effective dose to reduce fluid overload 3, 1
- Consider increasing diuretic dose before adding combination therapy if initial response is inadequate, as suggested by the European Heart Journal 1, 4
Disease-Modifying Therapy
- The American College of Cardiology recommends SGLT2 inhibitors (dapagliflozin or empagliflozin) to be initiated early as they have demonstrated mortality and morbidity benefits in HFpEF patients 3, 1
- The American College of Cardiology suggests considering mineralocorticoid receptor antagonists (MRAs) like spironolactone, particularly in patients with LVEF in the lower range of preservation (40-50%) 3, 5
- ARNIs (sacubitril/valsartan) may be beneficial in selected patients, especially women and those with LVEF below the upper range, as suggested by the American College of Cardiology and European Heart Journal 5, 1
Management of Comorbidities
- The American College of Cardiology recommends achieving optimal blood pressure control (<130/80 mmHg) using appropriate antihypertensive medications 3, 1
- The American Heart Association, as published in Circulation, suggests controlling rate using beta-blockers or non-dihydropyridine calcium channel blockers in HFpEF patients with atrial fibrillation 6
- The American College of Cardiology recommends prioritizing SGLT2 inhibitors for glycemic control given their additional heart failure benefits 3
Non-Pharmacological Interventions
- The European Heart Journal suggests prescribing supervised exercise training programs to improve functional capacity and quality of life 1
- The European Heart Journal recommends sodium restriction (<2-3g/day) and fluid restriction when appropriate 1, 7
Monitoring and Follow-up
- The American College of Cardiology recommends monitoring symptoms, vital signs, weight, renal function, and electrolytes regularly 3
- The European Heart Journal suggests adjusting diuretic doses based on congestion status to avoid overdiuresis which can lead to hypotension 1
- Consider wireless pulmonary artery pressure monitoring in selected patients with recurrent hospitalizations, as recommended by the American College of Cardiology and European Heart Journal 3, 1
Common Pitfalls to Avoid
- The American College of Cardiology and European Heart Journal recommend not delaying initiation of SGLT2 inhibitors which have proven mortality benefits 3, 1
- Avoid excessive diuresis which can lead to hypotension and impaired tolerance of other medications, as suggested by the European Heart Journal and other guidelines 1
Guideline-Directed Management of Heart Failure with Preserved Ejection Fraction
Pharmacological Interventions
- Thiazides can be added as adjunctive therapy in hypertensive patients or those with refractory edema despite loop diuretics, as recommended by the European Heart Journal 8
Non-Pharmacological Interventions
- Refer to supervised exercise training programs, which provide substantial improvements in aerobic exercise capacity and quality of life, as recommended by the American College of Cardiology 9
- Prescribe sodium restriction to <2-3 g/day to reduce congestive symptoms, as recommended by the European Heart Journal 8